Bli medlem
Bli medlem

Du är här


Phase Holographic: HoloMonitor provide vital information to development of improved child cancer treatment

In 2010 under the leadership of Associate Professor David Gisselsson
Nord at Lund University, research results developed in a
collaboration between Lund University Hospital, the Institute of
Cancer Research in London and Phase Holographic Imaging (PHI) where
published. These pre-clinical research results - to which PHI's
HoloMonitor® technology provided vital information - have now led to
an improved clinical treatment of malignant child cancer. The Swedish
Cancer Foundation recently granted Gisselsson Nord additional funding
to further develop the treatment.

"Last weeks $7.4 million grant to David Gisselsson Nord and other
cancer researchers at Lund University will create additional
opportunities for PHI and our local customers here in Lund, who
predominantly are cancer researchers," said CEO Peter Egelberg.

"We all like to see businesses we are working with succeed. But there
is always something a bit more when the technology leads to something
really special. I'm proud to be a part of PHI, both as adviser and
shareholder" - Ron Lowy, Denver.

More about David Gisselsson Nord

· David Gisselsson Nord Research Group -

· New method for identifying most aggressive childhood cancers -

· New method improves detection of malignant child cancer, interview
in Swedish press -

· Scientists at Lund University question leading theory of how
cancer arise, interview in Swedish radio -

· David Gisselsson and cancer research at Lund University receive 64
million kronor donation (in Swedish) -,c9860177

· Child cancer research awarded by the Fernström foundation (in
Swedish) -

· Article from 2010 in Proceedings of the National Academy of
Sciences (PNAS) -

For additional information, please contact:

Peter Egelberg, CEO
Tel: +46 703 19 42 74

Phase Holographic Imaging (PHI) leads the ground-breaking development
of time-lapse cytometry instrumentation and software. With the first
instrument introduced in 2011, the company today offers a range of
products for long-term quantitative analysis of living cell dynamics
that circumvent the drawbacks of traditional methods requiring toxic
stains. Headquartered in Lund, Sweden, PHI trades through a network
of international distributors. Committed to promoting the science and
practice of time-lapse cytometry, PHI is actively expanding its
customer base and scientific collaborations in cancer research,
inflammatory and autoimmune diseases, stem cell biology, gene
therapy, regenerative medicine and toxicological studies.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.